A review of cancer screening evaluation techniques, with some particular examples in breast cancer screening

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 168, Issue 4, 2005, Pages 657-677

  Warwick, Jane ^a   Duffy, Stephen W ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Epidemiology; Mammography; Screening

Indexed keywords

EID: 26844529404     PISSN: 09641998     EISSN: 1467985X     Source Type: Journal    
DOI: 10.1111/j.1467-985X.2005.00371.x     Document Type: Review

References (82)

1. Alexander, F. E., Anderson, T. J., Brown, H. K., Forrest, A. P. M., Hepburn, W., Kirkpatrick, A. E., Muir, B. B., Prescott, R. J. and Smith, A. (1999) 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet, 353, 1903-1908.
2. Baker, S. G. (1998) The Paired Availability Design: an Update. Dusseldorf: Medinform.
3. Baker, S. G., Erwin, D. and Kramer, B. S. (2003a) Estimating the cumulative risk of false positive cancer screenings. BMC Med. Res. Methodol., 3, 11.
4. Baker, S. G., Erwin, D., Kramer, B. S. and Prorok, P. C. (2003b) Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med. Res. Methodol., 3, 4.
5. Baker, S. G. and Kramer, B. S. (2003) A perfect correlate does not a surrogate make. BMC Med. Res. Methodol., 3, 16.
6. Baker, S. G. and Kramer, B. S. (2005) Simple maximum likelihood estimates of efficacy in randomized trials before-and-after studies, with implications for meta-analysis. Statist. Meth. Med. Res., to be published.
7. Baker, S. G., Kramer, B. S. and Prorok, P. C. (2002) Statistical issues in randomized trials of cancer screening. BMC Med. Res. Methodol., 2, 11.
8. Baker, S. G., Kramer, B. S. and Prorok, P. C. (2004) Comparing cancer mortality rates before-and-after a change in availability of screening in different regions: extension of the paired availability design. BMC Med. Res. Methodol., 4, 12.
9. Balslev, I., Axelsson, C. K., Zedeler, K., Rasmussen, B. B., Carstensen, B. and Mouridsen, H. T. (1994) The Nottingham-Prognostic-Index applied to 9,149 patients from the studies of the Danish-Breast-Cancer-Cooperative-Group. Breast Cancer Res. Treatmnt, 32, 281-290.
10. Bashir, S. and Esteve, J. (2000) Analysing the difference due to risk and demographic factors for incidence or mortality. Int. J. Epidem., 29, 878-884.
11. Berry, D. (2004) Screening mammography: a decision analysis. Int. J. Epidem., 33, 68.
12. Bjurstam, N., Bjorneld, L., Warwick, J., Sala, E., Duffy, S. W., Nyström, L., Walker, N., Cahlin, E., Eriksson, O., Hafström, L. O., Lingaas, H., Mattsson, J., Persson, S., Rudenstam, C. M., Salander, H., Save-Soderbergh, J. and Wahlin, T. (2003) The Gothenburg Breast Screening Trial. Cancer, 97, 2387-2396.
13. Black, W. C., Haggstrom, D. A. and Welch, H. G. (2002) All-cause mortality in randomized trials of cancer screening. J. Natn. Cancer Inst., 94, 167-173.
14. Blanks, R. G., Moss, S. M., McGahan, C. E., Quinn, M. J. and Babb, P. J. (2000) Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. Br. Med. J., 321, 665-669.
15. Botha, J. L., Bray, F., Sankila, R. and Parkin, D. M. (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur. J. Cancer, 39, 1718-1729.
16. Breast Screening Frequency Trial Group (2002) The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. Eur. J. Cancer, 38, 1458-1464.
17. Breslow, N. E. (1984) Extra-Poisson variation in log-linear models. Appl. Statist., 33, 38-44.
18. Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D. and Geys, H. (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics, 1, 49-67.
19. Buyske, S., Fagerstrom, R. and Ying, Z. L. (2000) A class of weighted log-rank tests for survival data when the event is rare. J. Am. Statist. Ass., 95, 249-258.
20. Chen, H. H., Duffy, S. W., Tabar, L. and Day, N. E. (1997) Markov chain models for progression of breast cancer, part 2: prediction of outcomes for different screening regimes. J. Epidem. Biostatist., 2, 25-35.
21. Chen, J. S. and Prorok, P. C. (1983) Lead time estimation in a controlled screening program. Am. J. Epidem., 118, 740-751.
22. Chen, T. H. H., Kuo, H. S., Yen, M. F., Lai, M. S., Tabar, L. and Duffy, S. W (2000) Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics, 56, 167-172.
23. Connor, R. J., Chu, K. C. and Smart, C. R. (1989) Stage-shift cancer screening model. J. Clin. Epidem., 42, 1083-1095.
24. Connor, R. J. and Prorok, P. C. (1994) Issues in the mortality analysis of randomized controlled trials of cancer screening. Contr. Clin. Trials, 15, 81-99.
25. Cronin, K. A., Weed, D. L., Connor, R. J. and Prorok, P. C. (1998) Case-control studies of cancer screening: theory and practice. J. Natn. Cancer Inst., 90, 498-504.
26. Cuzick, J., Edwards, R. and Segnan, N. (1997) Adjusting for non-compliance and contamination in randomized clinical trials. Statist. Med., 16, 1017-1029.
27. Cuzick, J., Sasieni, P., Davies, P., Adams, J., Normand, C., Frater, A., van Ballegooijen, M. and van den Akkervan Marie, E. (2000) A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer, 83, 561-565.
28. Day, N., McCann, J., Camilleri-Ferrante, C., Britton, P., Hurst, G., Cush, S. and Duffy, S. (1995) Monitoring interval cancers in breast screening programmes: the East Anglian experience. J. Med. Screen., 2, 180-185.
29. Day, N. E. and Walter, S. D. (1984) Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics, 40, 1-14.
30. Donner, A., Piaggio, G. and Villar, J. (2001) Statistical methods for the meta-analysis of cluster randomization trials. Statist. Meth. Med. Res., 10, 325-338.
31. Drossaert, C. H. C., Boer, H. and Seydel, E. R. (2002) Monitoring women's experiences during three rounds of breast cancer screening: results from a longitudinal study. J. Med. Screen., 9, 168-175.
32. Duffy, S. W., Cuzick, J., Tabar, L., Vitak, B., Chen, T. H.-H., Yen, M.-F. and Smith, R. A. (2002) Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl. Statist., 51, 235-243.
33. Duffy, S. W., Day, N. E., Tabar, L., Chen, H. H. and Smith, T. C. (1997) Markov models of breast tumor progression: some age-specific results. J. Natn. Cancer Inst. Monogr., 22, 93-97.
34. Duffy, S. W., Hill, C. and Esteve, J. (2001) Quantitative Methods for the Evaluation of Cancer Screening. London: Arnold.
35. Duffy, S. W., Tabar, L., Fagerberg, G., Gad, A., Grontoft, O., South, M. C. and Day, N. E. (1991) Breast screening, prognostic factors and survival - results from the Swedish 2 County Study. Br. J. Cancer, 64, 1133-1138.
36. Duffy, S. W., Tabar, L. and Smith, R. A. (2002) The mammographic screening trials: commentary on the recent work by Olsen and Gotzsche. CA Cancer J. Clin., 52, 68-71.
37. Eddy, D. M. (1986) A computer-based model for designing cancer control strategies. J. Natn. Cancer Inst., 2, 75-82.
38. Etzioni, R. D., Connor, R. J., Prorok, P. C. and Self, S. G. (1995) Design and analysis of cancer screening trials. Statist. Meth. Med. Res., 4, 3-17.
39. Fontana, R. S., Sanderson, D. R., Woolner, L. B., Taylor, W. F., Miller, W. E. and Muhm, J. R. (1986) Lung-cancer screening - the Mayo Program. J. Occupnl Environ. Med., 28, 746-750.
40. Freedman, D. A., Petitti, D. B. and Robins, J. M. (2004) On the efficacy of screening for breast cancer. Int. J. Epidem., 33, 43-55.
41. Freedman, L. S., Graubard, B. I. and Schatzkin, A. (1992) Statistical validation of intermediate endpoints for chronic disease. Statist. Med., 11, 167-178.
42. Gail, M. H., Pfeiffer, R., Houwelingen, H. C. and Carroll, R. J. (2001) On meta-analytic assessment of surrogate outcomes. Biostatistics, 3, 231-246.
43. Gøtzsche, P. C. and Olsen, O. (2000) Is screening for breast cancer with mammography justifiable? Lancet, 355, 129-134.
44. Hakama, M., Pukkala, E., Heikkila, M. and Kallio, M. (1997) Effectiveness of the public health policy for breast screening in Finland: population-based cohort study. Br. Med. J., 314, 864-867.
45. Hu, P. and Zelen, M. (1997) Planning clinical trials to evaluate early detection programmes. Biometrika, 84, 817-829.
46. International Agency for Research on Cancer Working Group on the Evaluation of Cancer-Preventive Strategies (2002) Breast Cancer Screening. Lyon: International Agency for Research on Cancer Press.
47. Kadafar, K. and Prorok, P. (1994) A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials. Statist. Med., 13, 569-586.
48. Larsson, L. G., Nystrom, L., Wall, S., Rutqvist, L., Andersson, I., Bjurstam, N., Fagerberg, G., Frisell, J. and Tabar, L. (1996) The Swedish randomised mammography screening trials: analysis of their effect on the breast cancer related excess mortality. J. Med. Screen., 3, 129-132.
49. Lidbrink, E. K., Tornberg, S. A., Azavedo, E. M., Frisell, J. O., Hjalmar, M. L., Leifland, K. S., Sahlstedt, T. B. and Skoog, L. (1994) The General Mammography Screening-Program in Stockholm - organization and first-round results. Acta Oncol., 33, 353-358.
50. Lin, D. Y., Fleming, T. R. and De Gruttola, V. (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Statist. Med., 16, 1515-1527.
51. Loeve, F., Boer, R., van Oortmarssen, G. J., van Ballegooijen, M. and Habbema, J. D. F. (1999) The MISCANCOLON simulation model for the evaluation of colorectal cancer screening. Comput. Biomed. Res., 32, 13-33.
52. Miller, A. B., To, T., Baines, C. J. and Wall, C. (2000) Canadian National Breast Screening Study-2:13-year results of a randomized trial in women aged 50-59 years. J. Natn. Cancer Inst., 92, 1490-1499.
53. Molenberghs, G., Burzykowski, T., Alonso, A. and Buyse, M. (2004) A perspective on surrogate end points in controlled clinical trials. Statist. Meth. Med. Res., 13, 177-206.
54. Mollison, J., Simpson, J. A., Campbell, M. K. and Grimshaw, J. M. (2000) Comparison of analytical methods for cluster randomised trials: an example from a primary care setting. J. Epidem. Biostatist., 5, 339-348.
55. Moss, S. M., Michel, M., Patnick, J., Johns, L., Blanks, R. and Chamberlain, J. (1995) Results from the NHS breast screening programme 1990-1993. J. Med. Screen., 2, 186-190.
56. Nixon, R., Prevost, T., Duffy, S., Tabar, L., Vitak, B. and Chen, H. (2000) Some random-effects models for the analysis of matched-cluster randomised trials: application to the Swedish two-county trial of breast-cancer screening. J. Epidem. Biostatist., 5, 349-358.
57. Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B. and Rutqvist, L. E. (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359, 909-919.
58. Olsen, O. and Gøtzsche, P. C. (2001) Cochrane review on screening for breast cancer with mammography. Lancet, 358, 1340-1342.
59. Organising Committee and Collaborators (1996) Breast cancer screening with mammography in women aged 40-49 years. Int. J. Cancer, 68, 693-699.
60. Paci, E., Boer, R., Zappa, M., Dekoning, H. J., Vanoortmarssen, G. J., Crocetti, E., Giorgi, D., Delturco, M. R. and Habbema, J. D. F. (1995) A model-based prediction of the impact on reduction in mortality by a breast-cancer screening-program in the City of Florence, Italy. Eur. J. Cancer A, 31, 348-353.
61. Paci, E., Duffy, S. W., Giorgi, D., Zappa, M., Crocetti, E., Vezzosi, V., Bianchi, S. and Del Turco, M. R. (2002) Quantification of the effect of mammographic screening on fatal breast cancers: the Florence Programme 1990-1996. Br. J. Cancer, 87, 65-69.
62. Paci, E., Warwick, J., Falini, P. and Duffy, S. W. (2004) Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J. Med. Screen., 11, 23-27.
63. Prentice, R. L. (1989) Surrogate end points in clinical trials: definition and operational criteria. Statist. Med., 8, 431-440.
64. Prorok, P. C. (1976) The theory of periodic screening I: lead time and proportion detected. Adv. Appl. Probab., 8, 127-143.
65. Sasieni, P. (2003) Evaluation of the UK. breast screening programmes. Ann. Oncol., 14, 1206-1208.
66. Self, S. G. and Etzioni, R. (1995) A likelihood ratio test for cancer screening trials. Biometrics, 51, 44-50.
67. Shapiro, S., Goldberg, J. D. and Hutchison, G. B. (1974) Lead time in breast cancer detection and implications for periodicity of screening. Am. J. Epidem., 100, 357-366.
68. Shapiro, S., Strax, P. and Venet, L. (1971) Periodic breast cancer screening in reducing mortality from breast cancer. J. Am. Med. Ass., 215, 1777-1785.
69. Stevenson, C. E. (1995) Statistical models for cancer screening. Statist. Meth. Med. Res., 4, 18-32.
70. Stockton, D., Davies, T., Day, N. and McCann, J. (1997) Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: earlier diagnosis or better treatment. Br. Med. J., 314, 472-475.
71. Tabar, L., Duffy, S. W., Vitak, B., Chen, H. H. and Prevost, T. C. (1999) The natural history of breast carcinoma - what have we learned from screening? Cancer, 86, 449-462.
72. Tabar, L., Duffy, S. W., Yen, M. F., Warwick, J., Vitak, B., Chen, H. H. and Smith, R. A. (2002) All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. J. Med. Screen., 9, 159-162.
73. Tabar, L., Fagerberg, G., Duffy, S. W., Day, N. E., Gad, A. and Grontoft, O. (1992) Update of the Swedish Two-County Program of Mammographic Screening for breast-cancer. Radial. Clin. N. Am., 30, 187-210.
74. Tabar, L., Gad, A., Holmberg, L. H., Ljungquist, U., Eklund, G., Fagerberg, C. J. G., Baldetorp, L., Grontoft, O., Lundstrom, B., Manson, J. C., Day, N. E. and Pettersson, F. (1985) Reduction in mortality from breast-cancer after mass-screening with mammography. Lancet, i, 829-832.
75. Tabar, L., Vitak, B., Chen, H. H., Duffy, S. W., Yen, M. F., Chiang, C. F., Krusemo, U. B., Tot, T. and Smith, R. A. (2000) The Swedish two-county trial twenty years later - updated mortality results and new insights from long-term follow-up. Radial. Clin. N. Am., 38, 625-651.
76. Tabar, L., Vitak, B., Yen, M. F., Chen, H. H. T., Smith, R. A. and Duffy, S. W. (2004) Number needed to screen: lives saved over 20years of follow-up in mammographic screening. J. Med. Screen., 11, 126-129.
77. Tabar, L., Yen, M. F., Vitak, B., Chen, H. H. T., Smith, R. A. and Duffy, S. W (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet, 361, 1405-1410.
78. Thornton, H., Edwards, A. and Baum, M. (2003) Women need better information about routine mammography. Br. Med. J., 327, 101-103.
79. Truong, M. T. and Munden, R. F. (2003) Lung cancer screening. Curr. Oncol. Rep., 5, 309-312.
80. Wilson, J. and Jungner, G. (1968) Principles and Practice of Screening for Disease. Geneva: World Health Organization.
81. Yen, M. F., Tabar, L., Vitak, B., Smith, R. A., Chen, H. H. and Duffy, S. W. (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur. J. Cancer, 39, 1746-1754.
82. Zelen, M. and Feinleib, M. (1969) On the theory of screening for chronic diseases. Biometrika, 56, 601-613.